These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18612701)

  • 1. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
    Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
    Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
    Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
    Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
    Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
    Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
    Tan H; Ye K; Wang Z; Tang H
    Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
    Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
    Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
    Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
    Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
    Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
    J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
    Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
    Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
    Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
    Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
    Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
    Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma.
    Tan H; Ye K; Wang Z; Tang H
    Transl Res; 2008 Sep; 152(3):143-9. PubMed ID: 18774544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.
    Montero-Conde C; Martín-Campos JM; Lerma E; Gimenez G; Martínez-Guitarte JL; Combalía N; Montaner D; Matías-Guiu X; Dopazo J; de Leiva A; Robledo M; Mauricio D
    Oncogene; 2008 Mar; 27(11):1554-61. PubMed ID: 17873908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
    Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
    Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma.
    Sethi K; Sarkar S; Das S; Rajput S; Mazumder A; Roy B; Patra S; Mohanty B; El-Naggar AK; Mandal M
    J Exp Ther Oncol; 2011; 9(3):187-99. PubMed ID: 22070050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.
    Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Zhan S; Xie K; Li QQ
    Anticancer Res; 2011 Oct; 31(10):3433-40. PubMed ID: 21965758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
    Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
    Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.